VYEPTI is indicated for the preventive treatment of migraine in adults.
VYEPTI is indicated for the preventive treatment of migraine in adults.

Hear how VYEPTI was the difference Chanci needed

Despite being on a preventive and an acute treatment, migraine dictated Chanci’s daily life

  • Inability to be present with friends and family
  • Isolated due to light and noise sensitivity
  • Frequent migraine days as well as daily headaches
  • Migraine attacks increasing in frequency and severity despite taking preventive medication
  • Increased use of acute medication without relief

Her neurologist recognized a change was needed and prescribed VYEPTI

REVIEW PATIENT IMPACT DATA
Chanci, 33, is a mother, wife, artist, and real VYEPTI patient

“My migraine attacks made me feel helpless. I needed to do something different. My neurologist and I decided to try VYEPTI.”

VYEPTI v

Chanci, real VYEPTI patient

Patient results may vary.

50% icon

of ~1,100 people with migraine surveyed in 2021 were dissatisfied with their ability to control their disease.1*

*Survey consisted of people diagnosed with migraine disease for ≥2 years and who satisfy at least 1 of the following: ≥8 migraine attacks in the prior month, have been prescribed a preventive migraine treatment, or are either currently taking or have previously taken a preventive migraine treatment.

Hear from more patients who were moved to VYEPTI

Lou, Lealani, and Electra, real VYEPTI patients

“When I would have my migraine attacks, my life was on hold. My experience on VYEPTI has given me the opportunity to do the things I used to do. It’s given me a second chance at life.”

Lou is a former college athlete whose chronic migraine slowed her down. Then her doctor prescribed VYEPTI.

VYEPTI v

Lou, real VYEPTI patient
arrow

“It has caused me to lose jobs...not experience things with my family. I almost missed my own wedding. Before VYEPTI I could not write things on a calendar and expect to keep them.”

Lealani had a hard time planning anything because chronic migraine kept getting in the way. Then she read about VYEPTI and asked her doctor.

VYEPTI v

Lealani, real VYEPTI patient
arrow

“I've just kind of been living day by day. I told myself, I can't keep living like this. There has to be something that can help me.”

Electra was struggling with chronic migraine and joined the VYEPTI clinical trial. Once it was approved, she started treatment.

VYEPTI v

Electra, real VYEPTI patient
arrow

Patient results may vary. Patients were compensated for their time.

IMPORTANT SAFETY INFORMATION AND INDICATION
CONTRAINDICATIONS

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, dyspnea, and rash, have occurred with VYEPTI in clinical trials and in the postmarketing setting. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

ADVERSE REACTIONS

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

For more information, please see the Full Prescribing Information and Patient Information.

IMPORTANT SAFETY INFORMATION AND INDICATION
CONTRAINDICATIONS

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, dyspnea, and rash, have occurred with VYEPTI in clinical trials and in the postmarketing setting. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

ADVERSE REACTIONS

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

For more information, please see the Full Prescribing Information and Patient Information.

Reference:

  1. National Headache Foundation. Preventing migraine attacks: a current perspective. April 2021. Accessed May 25, 2023. https://headaches.org/wp-content/uploads/2021/05/NHF-Preventing-Migraine-Attacks-Report-Updated-Reference-2021MAY10.pdf.
Site map Terms of Use Privacy Policy Contact us Cookie settings

© 2024 Lundbeck. All rights reserved. VYEPTI and VYEPTI GO are registered trademarks, and VYEPTI CONNECT and Migraine Victors Program are trademarks of Lundbeck Seattle BioPharmaceuticals, Inc. EPT-B-101196v3

All trademarks, logos, and brand names are the property of their respective owners. All company, product, and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.

This website is intended for US healthcare professionals only.